Please assess the completion status of the following clinical trial:

Trial Title: Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients aged ≥ 18 years, with measurable (defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (14)) metastatic (stage IV) breast cancer, and who are known to carry a BRCA1 mutation, are eligible.~* In addition, the following are required:~  * adequate hematologic~ * renal, and hepatic function~ * adequate recovery from recent surgery and/or radiation therapy~ * recovery from all prior treatment-related toxicities (to grade \< 2 according to National Cancer Institute Common Toxicity Criteria, Version3.0, except alopecia)~ * life expectancy of at least 12 weeks~ * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. -~* Patients could have received up to four prior chemotherapies for metastatic disease.~Exclusion Criteria:~* Patients with known brain metastases are not eligible.~* Patients previously treated with a platinum-based chemotherapy are not eligible.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).